Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer

Berlin, Jordan; Posey, James; Tchekmedyian, Simon; Hu, Eddie; Chan, D; Malik, Imtiaz; Yang, Liqiang; Amado, Rafael G.; Hecht, J. Randolph

doi:10.3816/ccc.2007.n.011

Cited by 96 publications

(53 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both objective response and stable disease rates in EGFR-negative cases appeared similar to EGFR-positive patients (9,11) and these results were confirmed in mCRC patients treated with panitumumab (12,13). Several studies have shown that there is no significant correlation between EGFR expression by IHC and efficacy of TKIs even in NSCLC patients (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26).…”

Section: Egfr Protein Expressionmentioning

confidence: 71%

EGFR genomic alterations in cancer: prognostic and predictive values

Bronte¹

2009

Front Biosci

View full text Add to dashboard Cite

The role of EGFR in cancer development and progression has been recognized for long time in a variety of human malignancies including lung, head and neck, colon, breast, ovary and glioma. Recently its role as a target of antineoplastic agents has also been identified and a variety of EGFR-targeted drugs is already being used in a clinical setting and others are at present under investigation. Many data involving EGFR protein expression are now available for the choice of anti-EGFR monoclonal antibodies in colorectal cancer and with regard to EGFR gene mutations for the choice of tyrosine kinase inhibitors in lung cancer. Other EGFR-related molecular factors, including the EGFR gene copy number, are currently under investigation. This review summarizes both preclinical and clinical available data regarding EGFR genomic alterations as prognostic and predictive factors

show abstract

Section: Egfr Protein Expressionmentioning

confidence: 71%

EGFR genomic alterations in cancer: prognostic and predictive values

Bronte¹

2009

Front Biosci

View full text Add to dashboard Cite

show abstract

“…Apart from lifestyle advices and loperamide administration, one should bear in mind that parenteral fluid replacement and normalization of electrolyte levels is essential in NCI-CTCAE Grade 3 diarrhoea (defecation more than 7 times per day or fecal incontinence, or necessity of hospitalization due to symptoms). If one fails to do so, calcium and magnesium electrolyte disturbances may increase in severity and acute renal failure may also develop (Berlin et al, 2007;Eaby, n. d.;EMA 2011b;Moy & Goss, 2007;Peeters et al, 2008;Pikó, 2009;Tuma, 2006;Widakowich et al, 2007).…”

Section: Diarrhoeamentioning

confidence: 99%

Panitumumab for the Treatment of Metastatic Colorectal Cancer

Pikó¹,

Bassam²,

Török³

et al. 2012

Colorectal Cancer - From Prevention to Patient Care

View full text Add to dashboard Cite

“…At this time, one small phase II trial has been published testing panitumumab with irinotecan-containing chemotherapy. 58 …”

Section: First-line Advanced Diseasementioning

confidence: 99%

Targeting the Epidermal Growth Factor Receptor in Colorectal Cancer

Chan¹,

Me²,

Gullick³

2007

European Oncology &Amp; Haematology

View full text Add to dashboard Cite

A crucial goal in the refinement of systemic cancer therapy is the achievement of high efficacy while minimising side effects. Conventional anticancer drugs target malignant cells to an extent, but are often associated with dose-limiting toxicity. One solution is to improve the specificity of the therapeutic agent based upon knowledge of a specific target. As our understanding of the molecular basis of cancer steadily progresses, the opportunities for the development of such improved treatments rise commensurately. The design of modern drug therapies is informed by the genetic and biochemical mechanisms responsible for the behaviour of malignant cells. One such endeavour includes the development of targeted drugs against the type I transmembrane kinase receptor epidermal growth factor receptor (EGFR). Following a brief outline of EGFR cancer biology, this article will provide an up-to-date synopsis of clinical research efforts attempting to exploit this receptor system in the setting of advanced colorectal cancer. The Epidermal Growth Factor Receptor FamilyEGFR was the earliest of four receptors discovered in the ErbB family of receptor tyrosine kinases. 1,2 Furthermore, it was this receptor that first identified a relationship between an activated oncogene and malignant transformation. 3 This 170kDa glycoprotein comprises an extracellular portion made up of four distinct sub-domains capable of conformational change. 4,5 It is anchored by a single-pass transmembrane domain that connects to a cytoplasmic tail harbouring tyrosine kinase activity. 6 EGFR and its three sibling receptors -HER-2/ErbB2, HER-3/ErbB3 and HER-4/ ErbB4 -transduce the effects of at least 11 different peptide ligands, including epidermal growth factor (EGF). 7 Signalling events initiated by such growth factors are involved in normal physiological cellular growth and proliferation, but are critically important in malignant transformation.The harbinger of growth factor signalling is the extracellular binding of ligands to one or more of these receptors, which induces receptor homoor hetero-dimerisation or oligomerisation. As a result, phosphorylation of kinase-domain tyrosine residues ensues. These serve as docking sites for various cytoplasmic proteins, which then propagate signalling via second messenger pathways through the cytoplasm. These include Ras/mitogenactivated protein (MAP) kinase, the Src kinase family, Janus kinase (JAK), signal transducer and activator of transcription (STAT), phosphoinositol 3 (PI3), kinase/Akt and other phospholipid metabolism pathways. Via induction of nuclear transcription factors, the end-product of signalling is stimulation of cellular processes such as proliferation, antiapoptosis, growth and migration. 6 Ligand stimulation also leads to increased internalisation of EGFR via endocytic pathways; ultimately, receptors are either recycled or destined for lysosomal degradation. 8 The system is hugely complex in that there are multiple levels of variability and control, which increases system robustness. 9,10 ...

show abstract

Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer

Cited by 96 publications

References 12 publications

EGFR genomic alterations in cancer: prognostic and predictive values

EGFR genomic alterations in cancer: prognostic and predictive values

Panitumumab for the Treatment of Metastatic Colorectal Cancer

Targeting the Epidermal Growth Factor Receptor in Colorectal Cancer

Contact Info

Product

Resources

About